Infinity Pharmaceuticals exercised an option this week to purchase worldwide royalty obligations ranging from 7% to 11% on sales of duvelisib (IPI-145) in oncology indications from Takeda Pharmaceutical for $52.5 million.
Carving out a successful career in biopharma isn't easy, for men or women. The failure rate of experimental drugs is astronomically high. And just because a company wins an approval is no...
AbbVie has agreed to hand over $275 million upfront to Infinity Pharmaceuticals in exchange for rights to develop and commercialize duvelisib, its oral PI3k-delta/gamma inhibitor for blood cancers. And the blockbuster-size deal for Infinity's lead program comes with $530 million in potential milestones.
Carl June and the Novartis/Penn team weren't the only players to grab the spotlight at the global gathering of hematology experts at the big American Society of Hematology meeting in New Orleans. Several companies touted new data for their therapies over the weekend, and FierceBiotech focused on a roundup of the news related to some top contenders in the field.
The Cambridge, MA-based biotech has agreed to pay Takeda $15 million and in exchange Millennium is ripping up its option to bag a 50/50 split on any of Infinity's PI3K inhibitors, including the lead program for IPI-145.
Infinity Pharmaceuticals has cut 20% of its employees as the drug developer advances its lead candidates without R&D dollars from Mundipharma International, the company revealed Tuesday. And the company also blamed its recent decision to end development of its lead anti-cancer compound saridegib for the staff cutbacks.
Independent monitors stepped in to shut down another mid-stage cancer study of Infinity Pharmaceuticals' ($INFI) lead drug saridegib after concluding that the experimental therapy was performing no better than a placebo.
Infinity Pharmaceuticals' ($INFI) lead therapy failed a critical mid-stage hurdle as investigators moved to shut down a study for pancreatic cancer after the treatment in combination with a common
Infinity Pharmaceuticals ($INFI) has some new wiggle room in its budget to develop its PI3K inhibitor intended to combat blood cancers and inflammation. Mundipharma International, Infinity's partner
Infinity Pharmaceuticals, a 2005 Fierce 15 company, has scooped up the global development and commercialization rights to a portfolio of oral PI3K inhibitors developed by Intellikine, including one